Ocular manifestations of intermediate cystinosis: To treat or not to treat?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: SAGE Publishing Country of Publication: United States NLM ID: 9110772 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1724-6016 (Electronic) Linking ISSN: 11206721 NLM ISO Abbreviation: Eur J Ophthalmol Subsets: MEDLINE
    • Publication Information:
      Publication: 2018- : Thousand Oaks, CA : SAGE Publishing
      Original Publication: Milano ; Birmingham, AL : Wichtig, c1991-
    • Subject Terms:
      Visual Acuity*; Cornea/*pathology ; Corneal Diseases/*etiology ; Cysteamine/*therapeutic use ; Cystinosis/*complications ; Tomography, Optical Coherence/*methods; Adult ; Corneal Diseases/diagnosis ; Corneal Diseases/drug therapy ; Cystine Depleting Agents/therapeutic use ; Cystinosis/diagnosis ; Cystinosis/drug therapy ; Female ; Follow-Up Studies ; Humans ; Microscopy, Confocal/methods ; Slit Lamp Microscopy ; Time Factors
    • Abstract:
      Purpose: To report a case of intermediate cystinosis with an atypical presentation in which a delayed non-treatment decision has been proved right over a large period of time.
      Methods: This is a unique case report of a patient who underwent full ophthalmologic evaluations including anterior chamber optical coherence tomography on a regular basis during a 7-year follow-up period.
      Results: A 30-year-old woman with photophobia was being studied by the Department of Nephrology with a suspicion of Alport syndrome. Slit-lamp examination showed iridescent deposits throughout the corneal anterior stroma and the inferior tarsal conjunctiva bilaterally. Anterior chamber optical coherence tomography showed stromal hyperreflectivity. CTNS gene was found to be positive for c.416C>T (Ser139Phe) mutation. The patient was offered oral and topical cysteamine which was refused. After a period of 5 years of follow-up, general health status remained stable, corneal disease showed no progression and photophobia complaints diminished. However, the patient was advised to start systemic and topical cysteamine because of the unknown development of the disease.
      Conclusion: In this reported case, a delayed non-treatment decision has been proved right contrary to published evidence of active treatment of photophobia. The decision whether to treat or not to treat corneal involvement of the disease is not straightforward. Besides biomicroscopic evaluations, patients' complaints and expectations should be taken into account.
    • Contributed Indexing:
      Keywords: Intermediate cystinosis; anterior chamber optical coherence tomography; cornea; cysteamine; cystine crystals
    • Accession Number:
      0 (Cystine Depleting Agents)
      5UX2SD1KE2 (Cysteamine)
    • Publication Date:
      Date Created: 20190511 Date Completed: 20210104 Latest Revision: 20220419
    • Publication Date:
      20240829
    • Accession Number:
      10.1177/1120672119848899
    • Accession Number:
      31074291